Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development.The Editors welcome:Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategiesDrug Evaluations reviewing the clinical and pharmacological data on a particular drugOriginal Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trialsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.
《研究药物专家意见》（ISSN 1354-3784 [印刷版]，1744-7658 [电子版]）是一份MEDLINE索引的、同行评审的国际期刊，发表关于药物临床前和早期临床开发的综述文章和原创论文，为未来的发展提供专家意见。编辑欢迎：综述涵盖药物或药物类别的特定适应症的临床前到II期数据，及其对未来治疗策略的潜在影响药物评价综述特定药物的临床和药理学数据原创研究论文报告I期和II期临床试验中药物的临床研究结果受众包括制药行业的科学家、管理人员和决策者，以及其他密切参与研发的人员。
Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1555237
The Jakinibs in systemic lupus erythematosus: progress and prospects
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1551358
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1557145
Cannabis for cancer – illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1561859
Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2018.1558202
Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1597053
BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1558442
Clinical drug development for dementia with Lewy bodies: past and present
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1681398
Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1694660
New drugs under investigation for the treatment of alopecias
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1568989
Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1657825
Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1678583
RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1583742
Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1559296
Investigational drugs for the treatment of binge eating disorder (BED): an update
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1692813
Targeting transcription factors in multiple myeloma: evolving therapeutic strategies
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1605354
BIIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1681967
Alzheimer’s disease: future drug development and the blood-brain barrier
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1627325
New drugs in early-stage clinical trials for allergic rhinitis
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1571581
Siponimod in the treatment of multiple sclerosis
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1676725
Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1555236
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1627326
New developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexia
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1557634
The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1650019
Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1694661
Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1667332
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1657403
The molecular basis for current targets of NASH therapies
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2020.1703949
TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1654993
Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2020.1703947
Investigational drugs for the treatment of acute myocardial infarction: focus on antiplatelet and anticoagulant agents
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1559814
Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1581763
Ridinilazole for the treatment of Clostridioides difficile infection
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1582640
Current advances in BCG-unresponsive non-muscle invasive bladder cancer
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1655730
Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1693999
Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1612557
Drugs under development for the treatment of functional dyspepsia and related disorders
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1673365
Emerging patient-specific treatment modalities in head and neck cancer – a systematic review
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1582642
Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1618269
Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1677606
Clinical profile of the functionally selective glucocorticoid receptor agonist BI 653048 in healthy male subjects
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1599859
Investigational drugs currently in phase II clinical trials for actinic keratosis
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1636030
Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1672655
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1598376
What can independent research for mesothelioma achieve to treat this orphan disease?
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1638363
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1696772
Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT)
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2020.1703180
Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1648430
Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2020.1703948
Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1692811
